Fraunhofer IZI and BioNTech to collaborate in the future

News /

The Fraunhofer Institute for Cell Therapy and Immunology IZI and BioNTech have signed a framework agreement in April 2022.

The Mainz-based company BioNTech and the Fraunhofer IZI's Molecular Drug Biochemistry and Therapy Development department, based in Halle (Saale), will collaborate in the field of biological assays in the future.

The Fraunhofer researchers will contribute their many years of expertise in establishing cellular and molecular biological analysis and model systems to the collaboration. In addition to cell-based assays, they will perform gene expression analyses as well as immunological and protein chemical methods for in vitro characterization.